Developer docs
API playgroundTry for free, no card

Search company profiles

Mammoth Biosciences

Full company profile

uuid0000cm1

Namestring
Mammoth Biosciences
Legal namestring
Mammoth Biosciences, Inc.
Websiteurl
mammoth.bio
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Mammoth Biosciences is a private biotechnology company founded in 2017–2018 by Jennifer Doudna (2020 Nobel laureate and CRISPR co-inventor), Trevor Martin, Janice Chen, and Lucas Harrington, headquartered in Brisbane, California. The company develops CRISPR-based platforms across two business lines: (1) in vivo gene editing therapeutics built on proprietary ultracompact nucleases (NanoCas and CasPhi) whose small size enables single-AAV and LNP delivery to extrahepatic tissues such as muscle and CNS, complemented by alternative editing modalities (base editing, epigenetic editing, RT editing) for precision and non-cutting gene modulation; and (2) the DETECTR molecular diagnostics platform, which uses CRISPR nucleases to detect disease-associated nucleic acids with results in 30–60 minutes.

The lead therapeutic program, MB-111, targets APOC3 knockout in the liver for Familial Chylomicronemia Syndrome and severe hypertriglyceridemia, and was nominated as Mammoth's first development candidate in April 2025. Underlying the portfolio is an AI-enabled protein discovery engine that screens one of the largest metagenomic databases and pairs in-silico prediction with high-throughput wet-lab screening to continuously generate new Cas systems.

Mammoth is pre-revenue commercially and monetizes almost exclusively through B2B partnership economics — upfront payments, development/regulatory/commercial milestones, and tiered royalties — rather than direct product sales. Anchor partnerships include Regeneron (2024: $100M upfront, up to $370M per target), Vertex (2021: $40M upfront, up to $650M potential), and Bayer (2022: $40M upfront for liver disease). The company has raised over $465M across venture rounds, achieving unicorn status in September 2021, and has a stated global footprint expanding into the Middle East via an MOU with Abu Dhabi's M42 and Department of Health in 2026. Customer segments are concentrated in major pharmaceutical and biotechnology partners, with secondary exposure to diagnostic companies and academic research institutions.

Short descriptiontext

Mammoth Biosciences is a private CRISPR biotechnology company that develops ultracompact nucleases (NanoCas, CasPhi) and the DETECTR diagnostics platform for in vivo gene editing and molecular detection, monetizing through strategic co-development and licensing partnerships with major pharmaceutical and biotechnology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR gene editing, in vivo therapeutics, molecular diagnostics, genetic medicine, genome engineering
Industry4 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
CRISPR Gene Editing Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

Major revenue stream through strategic co-development partnerships with pharmaceutical companies. Mammoth provides access to its CRISPR editing technologies and receives upfront payments, development/regulatory/commercial milestones, and tiered royalties on net sales. Key deals include Regeneron ($100M upfront + up to $370M per target) and Vertex ($40M upfront + up to $650M total potential).

mammoth.bio
2Diagnostic Platform Licensing
TypeLicensing Royalties
Description

DETECTR platform technology available for licensing to diagnostic companies. Partnership with Hamilton Company and MilliporeSigma for commercialization of CRISPR-based SARS-CoV-2 testing.

mammoth.bio
3Therapeutic Development
TypeOne Time License
Description

Development of proprietary therapeutic candidates through clinical stages with goal of commercializing gene editing therapies. Lead program MB-111 targeting triglycerides via APOC3 gene knockdown.

forbes.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1DETECTR
Description

CRISPR-based detection platform for molecular diagnostics that enables rapid detection of specific nucleic acids indicative of disease.

mammoth.bio
Core offering1 text field

Mammoth Biosciences develops proprietary CRISPR-Cas gene editing platforms (NanoCas, CasPhi) and editing modalities (base editing, epigenetic editing, RT editing) to enable in vivo gene editing therapies for rare and inherited diseases. The company also offers the DETECTR® molecular diagnostics platform for CRISPR-based detection of nucleic acids indicative of disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • MB-111 demonstrated robust triglyceride reduction in mouse models and non-human primates targeting APOC3 gene for FCS and sHTG treatment
+2 more records
Product overview1 text field

Mammoth Biosciences offers a CRISPR-based technology platform consisting of multiple integrated products. The core offering is the DETECTR® Platform for molecular diagnostics, which leverages CRISPR nucleases to detect specific nucleic acids for disease identification. For therapeutics, the company provides ultracompact CRISPR systems (NanoCas and CasPhi) along with novel editing modalities including Base Editing, Epigenetic Editing, and RT Editing platforms, all designed for in vivo gene therapy applications. These therapeutic components are uniquely compatible with single AAV and LNP delivery, enabling targeting of tissues beyond the liver. The lead therapeutic candidate MB-111 is advancing through development for triglyceride reduction.

Product and service1 record
1DETECTR® Platform
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Abu Dhabi's health company M42 partnered with Mammoth and Abu Dhabi Department of Health at BIO International Convention 2026 to develop CRISPR gene-editing therapies for rare and inherited diseases. Plans include introducing MB-111 into Abu Dhabi's clinical research ecosystem, establishing advanced therapy manufacturing capabilities including LNP production, and developing local gene-editing expertise.

2Abu Dhabi Department of Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Partnership with M42 and Mammoth Biosciences to develop CRISPR gene-editing therapies and position Abu Dhabi as a global hub for life sciences and precision medicine. Leverages insights from the Emirati Genome Programme.

gulfnews.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-04-25
Description

Collaboration to develop in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Mammoth receives $100M total upfront ($95M equity + $5M upfront payment) and is eligible for up to $370M per target in development, regulatory and commercial milestones plus royalty rates from single digits to mid-teens. Regeneron obtains broad access to Mammoth's editing technologies for 5.5 years with option to extend. Regeneron leads development and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-09
Description

Collaboration focused on liver disease using Mammoth's ultra-small CRISPR technology. Mammoth received $40M upfront payment. Bayer collaboration connects with their growing cell and gene therapy business.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

Collaboration to develop in vivo gene-editing therapies for serious diseases. Two in vivo indications. Mammoth received $40M upfront payment and investment, with potential for up to $650M in future payments plus tiered royalties on net sales. Vertex brings complementary AAV delivery technology via Affinia and track record in complex diseases.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to develop COVID-19 test using CRISPR-based platform.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CRISPR Therapeutics is a leading clinical-stage CRISPR gene editing company developing Cas9-based ex vivo and in vivo therapies, including Casgevy (the first FDA-approved CRISPR therapy). It directly competes with Mammoth in the gene editing therapeutic space and shares the same B2B pharma partnership model, though it relies on legacy Cas9 rather than ultracompact nucleases.

TypeDirect peer
Description

Intellia is a clinical-stage in vivo CRISPR therapeutics company with leading programs in transthyretin amyloidosis and hereditary angioedema using Cas9 delivered via LNP. It is a direct competitor to Mammoth's in vivo editing strategy and has demonstrated clinical proof-of-concept that Mammoth still needs to achieve.

TypeDirect peer
Description

Editas Medicine develops CRISPR-based gene editing therapies using both Cas9 and Cas12a nucleases for rare diseases including sickle cell disease and inherited retinal diseases. It directly competes with Mammoth in the gene editing platform space and pursues a similar partner-enabled commercialization strategy.

TypeDirect peer
Description

Beam Therapeutics is a clinical-stage company pioneering base editing, one of the same editing modalities Mammoth offers. It is a direct competitor in the precision gene editing field and shares Mammoth's B2B pharma partnership model, including a high-profile partnership with Verve Therapeutics.

TypeDirect peer
Description

Verve Therapeutics develops in vivo base editing therapies for cardiovascular disease, including an APOC3-targeting program that directly overlaps with Mammoth's MB-111 lead indication. Verve is a leading direct competitor in the in vivo gene editing space for dyslipidemias and cardiovascular indications.

TypeDirect peer
Description

Caribou Biosciences is a clinical-stage CRISPR genome editing company developing allogeneic CAR-T cell therapies using its Cas12a chRDNA platform. It shares Mammoth's heritage in novel Cas protein research and competes in the broader CRISPR platform space, though its focus is ex vivo cell therapy rather than in vivo editing.

TypeDirect peer
Description

Sherlock Biosciences is a CRISPR-based molecular diagnostics company that developed the SHERLOCK platform, a direct competitor to Mammoth's DETECTR platform. Both companies spun out of CRISPR pioneer labs (Doudna and Zhang respectively) and compete in CRISPR-based nucleic acid detection for infectious disease and oncology diagnostics.

TypeDirect peer
Description

Prime Medicine develops prime editing therapies, a precision gene editing modality that overlaps with Mammoth's RT editing and base editing platforms. It is a direct competitor in next-generation gene editing modalities and shares Mammoth's strategic partnership approach with major pharma.

TypeDirect peer
Description

Arbor Biotechnologies is a gene editing company that discovered novel Cas proteins through metagenomic mining, directly mirroring Mammoth's AI-enabled protein discovery approach. It pursues both therapeutic in vivo editing and ex vivo cell therapy, making it a closely comparable platform peer.

TypeOthers
Description

Synthego is a genome engineering tools company providing synthetic CRISPR guides and cell engineering services. It is a technology supplier to Mammoth (providing modified guides for ex vivo sickle cell therapy research) and an enabling ecosystem participant in the broader CRISPR tools and reagents market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mammoth Biosciences

CRISPR Gene Editing Therapeuticsmammoth.bio

Mammoth Biosciences is a private CRISPR biotechnology company that develops ultracompact nucleases (NanoCas, CasPhi) and the DETECTR diagnostics platform for in vivo gene editing and molecular detection, monetizing through strategic co-development and licensing partnerships with major pharmaceutical and biotechnology companies.

What Mammoth Biosciences does

Mammoth Biosciences is a private biotechnology company founded in 2017–2018 by Jennifer Doudna (2020 Nobel laureate and CRISPR co-inventor), Trevor Martin, Janice Chen, and Lucas Harrington, headquartered in Brisbane, California. The company develops CRISPR-based platforms across two business lines: (1) in vivo gene editing therapeutics built on proprietary ultracompact nucleases (NanoCas and CasPhi) whose small size enables single-AAV and LNP delivery to extrahepatic tissues such as muscle and CNS, complemented by alternative editing modalities (base editing, epigenetic editing, RT editing) for precision and non-cutting gene modulation; and (2) the DETECTR molecular diagnostics platform, which uses CRISPR nucleases to detect disease-associated nucleic acids with results in 30–60 minutes.

The lead therapeutic program, MB-111, targets APOC3 knockout in the liver for Familial Chylomicronemia Syndrome and severe hypertriglyceridemia, and was nominated as Mammoth's first development candidate in April 2025. Underlying the portfolio is an AI-enabled protein discovery engine that screens one of the largest metagenomic databases and pairs in-silico prediction with high-throughput wet-lab screening to continuously generate new Cas systems.

Mammoth is pre-revenue commercially and monetizes almost exclusively through B2B partnership economics — upfront payments, development/regulatory/commercial milestones, and tiered royalties — rather than direct product sales. Anchor partnerships include Regeneron (2024: $100M upfront, up to $370M per target), Vertex (2021: $40M upfront, up to $650M potential), and Bayer (2022: $40M upfront for liver disease). The company has raised over $465M across venture rounds, achieving unicorn status in September 2021, and has a stated global footprint expanding into the Middle East via an MOU with Abu Dhabi's M42 and Department of Health in 2026. Customer segments are concentrated in major pharmaceutical and biotechnology partners, with secondary exposure to diagnostic companies and academic research institutions.

Mammoth Biosciences firmographics

Firmographics
Name
Mammoth Biosciences
Legal name
Mammoth Biosciences, Inc.
Website
https://mammoth.bio
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Mammoth Biosciences is a private CRISPR biotechnology company that develops ultracompact nucleases (NanoCas, CasPhi) and the DETECTR diagnostics platform for in vivo gene editing and molecular detection, monetizing through strategic co-development and licensing partnerships with major pharmaceutical and biotechnology companies.
Ownership category
akta.pro rank

Mammoth Biosciences industry classification

Industry
Product category
CRISPR Gene Editing Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • CRISPR gene editing
  • In vivo therapeutics
  • Molecular diagnostics
  • Genetic medicine
  • Genome engineering

Where Mammoth Biosciences is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mammoth Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Partnerships and Licensing: Major revenue stream through strategic co-development partnerships with pharmaceutical companies. Mammoth provides access to its CRISPR editing technologies and receives upfront payments, development/regulatory/commercial milestones, and tiered royalties on net sales. Key deals include Regeneron ($100M upfront + up to $370M per target) and Vertex ($40M upfront + up to $650M total potential).
  2. Diagnostic Platform Licensing: DETECTR platform technology available for licensing to diagnostic companies. Partnership with Hamilton Company and MilliporeSigma for commercialization of CRISPR-based SARS-CoV-2 testing.
  3. Therapeutic Development: Development of proprietary therapeutic candidates through clinical stages with goal of commercializing gene editing therapies. Lead program MB-111 targeting triglycerides via APOC3 gene knockdown.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Mammoth Biosciences product offering

Product offering

Core offering

Mammoth Biosciences develops proprietary CRISPR-Cas gene editing platforms (NanoCas, CasPhi) and editing modalities (base editing, epigenetic editing, RT editing) to enable in vivo gene editing therapies for rare and inherited diseases. The company also offers the DETECTR® molecular diagnostics platform for CRISPR-based detection of nucleic acids indicative of disease.

Product overview

Mammoth Biosciences offers a CRISPR-based technology platform consisting of multiple integrated products. The core offering is the DETECTR® Platform for molecular diagnostics, which leverages CRISPR nucleases to detect specific nucleic acids for disease identification. For therapeutics, the company provides ultracompact CRISPR systems (NanoCas and CasPhi) along with novel editing modalities including Base Editing, Epigenetic Editing, and RT Editing platforms, all designed for in vivo gene therapy applications. These therapeutic components are uniquely compatible with single AAV and LNP delivery, enabling targeting of tissues beyond the liver. The lead therapeutic candidate MB-111 is advancing through development for triglyceride reduction.

Differentiator

Problem solved

Functional benefit

Brands

  • DETECTR: CRISPR-based detection platform for molecular diagnostics that enables rapid detection of specific nucleic acids indicative of disease.

Products and services

  • DETECTR® Platform

Quantifiable outcome

  • MB-111 demonstrated robust triglyceride reduction in mouse models and non-human primates targeting APOC3 gene for FCS and sHTG treatment
  • +2 more outcomes

Companies that use Mammoth Biosciences

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Mammoth Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Mammoth Biosciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

  • M42coreStrategic or Co-development Partner · 25 June 2026Abu Dhabi's health company M42 partnered with Mammoth and Abu Dhabi Department of Health at BIO International Convention 2026 to develop CRISPR gene-editing therapies for rare and inherited diseases. Plans include introducing MB-111 into Abu Dhabi's clinical research ecosystem, establishing advanced therapy manufacturing capabilities including LNP production, and developing local gene-editing expertise.
  • Abu Dhabi Department of HealthcoreStrategic or Co-development Partner · 25 June 2026Partnership with M42 and Mammoth Biosciences to develop CRISPR gene-editing therapies and position Abu Dhabi as a global hub for life sciences and precision medicine. Leverages insights from the Emirati Genome Programme.
  • Regeneron PharmaceuticalsflagshipStrategic or Co-development Partner · 25 April 2024Collaboration to develop in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Mammoth receives $100M total upfront ($95M equity + $5M upfront payment) and is eligible for up to $370M per target in development, regulatory and commercial milestones plus royalty rates from single digits to mid-teens. Regeneron obtains broad access to Mammoth's editing technologies for 5.5 years with option to extend. Regeneron leads development and commercialization.
  • BayercoreStrategic or Co-development Partner · 9 January 2022Collaboration focused on liver disease using Mammoth's ultra-small CRISPR technology. Mammoth received $40M upfront payment. Bayer collaboration connects with their growing cell and gene therapy business.
  • Vertex PharmaceuticalscoreStrategic or Co-development Partner · 26 October 2021Collaboration to develop in vivo gene-editing therapies for serious diseases. Two in vivo indications. Mammoth received $40M upfront payment and investment, with potential for up to $650M in future payments plus tiered royalties on net sales. Vertex brings complementary AAV delivery technology via Affinia and track record in complex diseases.
  • GSK Consumer HealthcareminorStrategic or Co-development PartnerCollaboration to develop COVID-19 test using CRISPR-based platform.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Mammoth Biosciences competitors and assessment

Company assessment

Direct peers

  • CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage CRISPR gene editing company developing Cas9-based ex vivo and in vivo therapies, including Casgevy (the first FDA-approved CRISPR therapy). It directly competes with Mammoth in the gene editing therapeutic space and shares the same B2B pharma partnership model, though it relies on legacy Cas9 rather than ultracompact nucleases.
  • Intellia Therapeutics: Intellia is a clinical-stage in vivo CRISPR therapeutics company with leading programs in transthyretin amyloidosis and hereditary angioedema using Cas9 delivered via LNP. It is a direct competitor to Mammoth's in vivo editing strategy and has demonstrated clinical proof-of-concept that Mammoth still needs to achieve.
  • Editas Medicine: Editas Medicine develops CRISPR-based gene editing therapies using both Cas9 and Cas12a nucleases for rare diseases including sickle cell disease and inherited retinal diseases. It directly competes with Mammoth in the gene editing platform space and pursues a similar partner-enabled commercialization strategy.
  • Beam Therapeutics: Beam Therapeutics is a clinical-stage company pioneering base editing, one of the same editing modalities Mammoth offers. It is a direct competitor in the precision gene editing field and shares Mammoth's B2B pharma partnership model, including a high-profile partnership with Verve Therapeutics.
  • Verve Therapeutics: Verve Therapeutics develops in vivo base editing therapies for cardiovascular disease, including an APOC3-targeting program that directly overlaps with Mammoth's MB-111 lead indication. Verve is a leading direct competitor in the in vivo gene editing space for dyslipidemias and cardiovascular indications.
  • Caribou Biosciences: Caribou Biosciences is a clinical-stage CRISPR genome editing company developing allogeneic CAR-T cell therapies using its Cas12a chRDNA platform. It shares Mammoth's heritage in novel Cas protein research and competes in the broader CRISPR platform space, though its focus is ex vivo cell therapy rather than in vivo editing.
  • Sherlock Biosciences: Sherlock Biosciences is a CRISPR-based molecular diagnostics company that developed the SHERLOCK platform, a direct competitor to Mammoth's DETECTR platform. Both companies spun out of CRISPR pioneer labs (Doudna and Zhang respectively) and compete in CRISPR-based nucleic acid detection for infectious disease and oncology diagnostics.
  • Prime Medicine: Prime Medicine develops prime editing therapies, a precision gene editing modality that overlaps with Mammoth's RT editing and base editing platforms. It is a direct competitor in next-generation gene editing modalities and shares Mammoth's strategic partnership approach with major pharma.
  • Arbor Biotechnologies: Arbor Biotechnologies is a gene editing company that discovered novel Cas proteins through metagenomic mining, directly mirroring Mammoth's AI-enabled protein discovery approach. It pursues both therapeutic in vivo editing and ex vivo cell therapy, making it a closely comparable platform peer.

Others

  • Synthego: Synthego is a genome engineering tools company providing synthetic CRISPR guides and cell engineering services. It is a technology supplier to Mammoth (providing modified guides for ex vivo sickle cell therapy research) and an enabling ecosystem participant in the broader CRISPR tools and reagents market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Mammoth Biosciences social profiles

Digital presence

Mammoth Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mammoth Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Mammoth Biosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mammoth Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mammoth Biosciences

What does Mammoth Biosciences do?

Mammoth Biosciences develops proprietary CRISPR-Cas gene editing platforms (NanoCas, CasPhi) and editing modalities (base editing, epigenetic editing, RT editing) to enable in vivo gene editing therapies for rare and inherited diseases. The company also offers the DETECTR® molecular diagnostics platform for CRISPR-based detection of nucleic acids indicative of disease.

Is Mammoth Biosciences a public or private company?

Mammoth Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mammoth Biosciences founded?

Mammoth Biosciences was founded in 2018. It employs 101 to 250 people.

Where is Mammoth Biosciences based?

Mammoth Biosciences is headquartered in Brisbane, United States, in the North America region.

How does Mammoth Biosciences make money?

Three revenue lines are on record. Strategic Partnerships and Licensing is the primary driver. The others are diagnostic Platform Licensing and therapeutic Development.

Who are Mammoth Biosciences's main competitors?

Direct peers on record are CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, Beam Therapeutics, Verve Therapeutics, Caribou Biosciences, Sherlock Biosciences, Prime Medicine and Arbor Biotechnologies. Synthego is listed as an others.

Does Mammoth Biosciences have an API?

No public API is recorded for Mammoth Biosciences.

What industry is Mammoth Biosciences in?

Mammoth Biosciences's product category is CRISPR Gene Editing Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNew England Biolabs® and Mammoth Biosciences® Announce Global Licensing Agreement and Commercial Launch of MB-CasFire™ to Accelerate Isothermal Amplification-Based Assay DevelopmentNew England Biolabs and Mammoth Biosciences announced a global licensing agreement under which NEB will manufacture and distribute Mammoth's MB-CasFire CRISPR enzyme. The enzyme enables one-pot isothermal amplification assays, including LAMP and RPA, with broad temperature activity from 37-65°C. It is available for research use only and globally through NEB.CRISPR MedicineNews: Miniscule Cas nucleases do a Mammoth’s jobMammoth Biosciences CSO Lucas Harrington explains that compact Cas nucleases like Cas14 and CasΦ are half the size of Cas9 but function via homodimer formation. The company is pre-clinical, focusing on in vivo therapies, and expects to disclose specific indications soon.MediaofficeDepartment of Health - Abu Dhabi signs agreements to support translation of gene editing from research into clinical impactAbu Dhabi's Department of Health signed strategic agreements with Children's Hospital of Philadelphia, Mammoth Biosciences, and Arbor Biotechnologies to accelerate the clinical translation of gene-editing therapies for rare diseases. These partnerships aim to leverage insights from the Emirati Genome Program to enhance research, manufacturing capabilities, and patient outcomes in the region. The initiative is part of a broader mission to strengthen Abu Dhabi's life sciences ecosystem through international collaboration.GulfNewsAbu Dhabi, M42 and Mammoth Biosciences Partner to Advance CRISPR Gene-Editing Therapies and Precision Medicine HubAbu Dhabi's Department of Health, M42, and US-based Mammoth Biosciences signed a memorandum of understanding at the BIO International Convention 2026 in San Diego to develop CRISPR gene-editing therapies for rare and inherited diseases. The partnership leverages insights from the Emirati Genome Programme and includes plans to introduce Mammoth's lead clinical candidate MB-111 into Abu Dhabi's clinical research ecosystem, establish advanced therapy manufacturing capabilities starting with lipid nanoparticle production, and develop local expertise in gene-editing technologies. The collaboration aligns with Abu Dhabi's Health, Endurance, Longevity and Medicine cluster aimed at positioning the emirate as a global hub for life sciences and precision medicine.openPR.comCRISPR-Based Diagnostics Market Size to Reach USD 12.09 Billion by 2033 as Rapid Molecular Testing, Reagent Demand, and Point-of-Care Innovation Expand Commercial PotentialThe global CRISPR-Based Diagnostics Market reached USD 3.04 billion in 2024 and is projected to grow to USD 12.09 billion by 2033, reflecting a CAGR of 16.7% during the forecast period, as CRISPR technology transitions from research-focused genome editing toward practical molecular diagnostics platforms. The market is being shaped by growing demand for rapid molecular testing, point-of-care workflows, and consumables such as kits and reagents, with Cas12-based detection emerging as a leading commercial technique segment holding approximately 47% market share. Key commercial players including Mammoth Biosciences (with its DETECTR platform), Integrated DNA Technologies (which announced portfolio expansion in July 2025), and OraSure Technologies are driving platform development and assay infrastructure, while regulatory frameworks from the FDA and supportive policy in Japan provide a favorable backdrop for commercialization.openPR.comCRISPR-Based Diagnostics Market to Reach US$ 12.09 Billion by 2033 Driven by Rapid Molecular Testing, Advancements in CRISPR Technologies, and Growing Demand for Point-of-Care DiagnosticsThe global CRISPR-based diagnostics market is projected to grow from US$3.04 billion in 2024 to US$12.09 billion by 2033, representing a compound annual growth rate of 16.7% over the forecast period 2025–2033. Growth is driven by increasing demand for rapid, accurate, and cost-effective diagnostic solutions for infectious diseases, genetic disorders, and point-of-care testing, supported by rising investments in molecular diagnostics, biotechnology research, and precision medicine. Key industry participants including Thermo Fisher Scientific and Danaher Corporation are pursuing strategic expansions and collaborations in CRISPR technologies, while companies such as Sherlock Biosciences, Mammoth Biosciences, and Intellia Therapeutics continue advancing product development and R&D in CRISPR-based detection platforms.ForbesThe Startup Building An Operating System For Biotech AITamarind Bio, a Y Combinator-incubated startup that builds software infrastructure enabling scientists to seamlessly use multiple AI models for drug discovery, announced it raised a $12 million Series A round led by Dimension Capital, bringing its total funding to $13.6 million. The company, which has been cash-flow positive since inception, counts pharmaceutical and biotech companies including Boehringer Ingelheim, Bayer, Mammoth Biosciences and Adimab among its customers. Tamarind Bio plans to use the funding to double its 12-person headcount and continue software development, having achieved 700% growth over the past year without a sales staff.InsideprecisionmedicineReporter’s Notebook: Gene Editing’s Long Road from Theory to TherapyAt the 2026 J.P. Morgan Healthcare Conference, four gene editing companies—Mammoth Biosciences, Caribou Biosciences, Stylus Medicine, and RheumaGen—presented clinical and strategic updates signaling the sector's shift from theoretical promise toward commercial viability, with each pursuing distinct approaches to CAR T cell therapy and genetic disease treatment. Caribou Biosciences reported Phase I results for its off-the-shelf CAR T therapy Vispa-cel in 84 lymphoma patients with response rates comparable to approved autologous therapies, while Mammoth announced its first clinical program MB-111 targeting triglycerides via APOC3 gene knockdown, and Stylus revealed plans to move beyond CRISPR toward a phage-derived recombinase platform for in vivo CAR T delivery. The article suggests gene editing is entering a more demanding phase where clinical proof points and commercial viability now matter more than technological novelty, as multiple companies race to transform cell therapy from bespoke procedures into broadly accessible treatments.BetaNewsScientists say finding extraterrestrial life and curing all genetic diseases could both happen in the next decadeScientists at the Dubai Future Forum 2025 (November 18-19) predicted that extraterrestrial life could be discovered within a decade through advances in exoplanet atmospheric studies, and that all known genetic diseases could be cured in the same timeframe due to rapid progress in gene editing technology. Dr. Trevor Martin, CEO of Mammoth Biosciences, claimed gene editing could deliver one-time cures reshaping healthcare, while Dr. Nikku Madhusudhan of Cambridge said ongoing detection of carbon-based molecules in exoplanet atmospheres suggests a "good chance" of finding life beyond Earth.